An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CVRx, Inc. (NASDAQ: CVRX) plans to release fourth quarter 2023 financial and operating results on January 25th, 2024. The company is a commercial-stage medical device company focused on developing, manufacturing, and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases. A conference call to review the results will be hosted at 4:30pm Eastern Time the same day, with a live webcast available on the investor relations page of the Company’s website at ir.cvrx.com.
Positive
None.
Negative
None.
MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact: Mark Klausner or Mike Vallie ICR Westwicke 443-213-0501 ir@cvrx.com
The release date for CVRx, Inc. (NASDAQ: CVRX) fourth quarter 2023 financial and operating results is on January 25th, 2024.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company focused on developing, manufacturing, and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases.
The conference call for CVRx, Inc. (NASDAQ: CVRX) fourth quarter 2023 financial and operating results can be listened to on the investor relations page of the Company’s website at ir.cvrx.com or by dialing 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers.
cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.
